EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

FLOWER MOUND, Texas, USA, Nov. 19, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, unveiled the Oculan Lighting Platform, an innovative lighting solution designed to provide consistent, high-quality illumination, allowing surgeons to focus on delivering the highest standard of care.In today's operating rooms, where precision and accuracy are critical, even the smallest challenges may impact surgical outcomes – factors which may impede a surgeon's ability to see clearly and ...

Stryker Corporation (SYK) has announced the launch of the next generation of SurgiCount+ within its sponge management portfolio.SurgiCount+, integrated with Stryker’s Triton technology, is likely to provide solutions for retained surgical sponges and blood-loss assessment. Integrating these previously separate digital solutions is likely to provide the added benefit of more efficiency and a streamlined workflow for hospitals.Likely Trend of SYK Stock Following the NewsFollowing the announcement, shares of t ...

Maternal mortality has been rising in the U.S. for decades,1 with approximately 50,000 cases of severe maternal morbidity occurring each year.2 Notably, 70% of pregnancy-related deaths due to hemorrhage are preventable.3 Stryker's Triton software includes AI technology that can differentiate blood from other fluids and a Bluetooth scale that batch weighs blood-soaked items to help assess blood loss. This provides hospital staff with real-time information to help coordinate the clinical team's hemorrhage res ...

Stryker Corporation (SYK) reported third-quarter 2024 adjusted earnings per share (EPS) of $2.87, which beat the Zacks Consensus Estimate of $2.78 by 3.2%. The bottom line also improved 16.7% year over year. GAAP EPS was $2.16, up 20% from the year-ago quarter's level. Revenue Details Revenues totaled $5.49 billion, beating the Zacks Consensus Estimate by 2.3%. The top line also improved 11.9% on a year-over-year basis and 12% at constant currency (cc). Revenues by Geography Revenues in the United States am ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 Michigan (State of incorporation) 1941 Stryker WayPortage, | --- | --- | |-------|--------------------------------------------| | | 38-1239739 | | | (I.R.S. Emplo ...

Financial Data and Key Metrics - The company delivered robust organic sales growth of 11.5% in Q3 2024, with strong double-digit growth in MedSurg and Neurotechnology, and nearly 10% growth in Orthopedics and Spine [6] - Adjusted quarterly EPS was $2.87, reflecting 16.7% growth compared to Q3 2023 [9] - Full-year 2024 organic sales growth guidance was narrowed to 9.5% to 10%, with adjusted EPS expected to be $12 to $12.10 [9] - The company achieved a 100 basis points margin expansion in 2024 and remains committed to 200 basis points of margin expansion by the end of 2025 [10] Business Line Performance - MedSurg and Neurotechnology saw constant currency sales growth of 12.9% and organic sales growth of 12.7%, driven by strong demand in surgical technologies, endoscopy, and medical businesses [19][20][21] - Orthopedics and Spine reported constant currency sales growth of 10.8% and organic growth of 9.7%, with strong performances in hips, knees, and trauma/extremities businesses [24][25] - The U.S. knee business grew 8.4% organically, driven by robotic-assisted knee procedures and Mako installations, while the U.S. hip business grew 10.9% organically [24][25] Market Performance - Growth was balanced between the U.S. and international markets, with both regions rising double digits organically [7] - International organic sales growth was 11.7%, driven by strong performances in Canada, the UK, Australia, New Zealand, Japan, and emerging markets [18][23] - The company completed several acquisitions, including Care.ai, NICO Corporation, and Vertos Medical, which are expected to contribute approximately $300 million to sales in 2025 [8][15] Strategic Direction and Industry Competition - The company remains committed to growth through acquisitions, with a strong deal pipeline and healthy financial capacity [9] - The company is focused on product innovation, healthy procedure volumes, and commercial execution to drive growth [10] - The Mako robotic platform continues to gain traction, with record Q3 installations and high utilization rates globally [12] Management Commentary on Operating Environment and Future Outlook - Management highlighted strong demand for capital products and procedural volumes, with expectations of sustained momentum through the end of 2024 [11][12] - The company is on track to achieve its margin expansion goals, driven by pricing initiatives, cost management, and operational efficiencies [10][26] - Management expressed confidence in the sustainability of double-digit growth in the medical business, driven by innovation and strong leadership [34] Other Important Information - The company ended Q3 with approximately $4.7 billion in cash, marketable securities, and short-term investments, with total debt of $15.5 billion [29] - Year-to-date cash from operations was $2.3 billion, an increase of $120 million from 2023, driven by higher earnings and improvements in inventory and accounts payable [30] Q&A Session Summary Question: Medical Business Growth Sustainability - The medical business has been the company's highest-growing division over the past five years, driven by innovation in products like ProCuity, Wireless Stretchers, and LIFEPAK 35 [34] - Management expects double-digit growth in the medical division to continue, although not necessarily at 18% every quarter [34] Question: Impact of Hurricanes on Q4 Guidance - Management does not expect significant disruptions from hurricanes in Q4 and aims to finish at the high end of the 9.5% to 10% organic growth guidance [36] Question: 2025 Growth and Margin Expansion - The company is committed to 100 basis points of operating margin expansion in 2025, driven by cost management, pricing initiatives, and operational efficiencies [39][41] - Management expects strong momentum to continue into 2025, with further details to be provided in January [39] Question: Mako Utilization and Growth - Mako installations and utilization rates remain strong globally, with record Q3 installations and high utilization rates driving growth in hips and knees businesses [12][79] - The company expects continued growth in Mako utilization, particularly in international markets like Japan [121] Question: Pricing Trends and Sustainability - The company achieved positive pricing growth in Q3, with a 1.2% favorable impact, driven by pricing initiatives in both U.S. and international markets [17][126] - Management expects pricing trends to remain favorable, with continued focus on contract negotiations and pricing strategies [126] Question: M&A Strategy and Impact - The company completed seven acquisitions in 2024, investing approximately $1.6 billion, with expected contributions of $300 million to sales in 2025 [15][71] - Management remains active on the M&A front, with a strong pipeline of deals and significant financial capacity [72] Question: Spine and Shoulder Robotics - Early feedback on Mako Spine and Copilot has been positive, with both products performing as expected in initial cases [53][54] - Management is optimistic about the potential of Mako Shoulder, which is on track to launch at the end of 2024 [14][108] Question: International Market Opportunities - The company sees significant growth opportunities in international markets, particularly in MedSurg and Neurotechnology, with a focus on expanding sales forces and product penetration [102][104] Question: Cementless Knees and Hips - The company has a strong position in cementless knees, with long-term data supporting the success of its cementless offerings [116] - Management expects continued growth in cementless hips, driven by the success of the Insignia stem and Mako robotic platform [119][120] Question: Orthopedics Market Share and Growth - The company continues to gain market share in orthopedics, driven by the Mako platform, product innovation, and strong sales execution [130][131] - Management expects sustained growth in orthopedics, particularly in trauma and extremities, with strong performances in core trauma and biologics [82][83]

For the quarter ended September 2024, Stryker (SYK) reported revenue of $5.49 billion, up 11.9% over the same period last year. EPS came in at $2.87, compared to $2.46 in the year-ago quarter. The reported revenue represents a surprise of +2.31% over the Zacks Consensus Estimate of $5.37 billion. With the consensus EPS estimate being $2.78, the EPS surprise was +3.24%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Stryker (SYK) came out with quarterly earnings of $2.87 per share, beating the Zacks Consensus Estimate of $2.78 per share. This compares to earnings of $2.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.24%. A quarter ago, it was expected that this medical device maker would post earnings of $2.79 per share when it actually produced earnings of $2.81, delivering a surprise of 0.72%.Over the last four quarters, the compan ...

Exhibit 99.1 STRYKER REPORTS THIRD QUARTER 2024 OPERATING RESULTS Portage, Michigan - October 29, 2024 - Stryker (NYSE:SYK) reported operating results for the third quarter of 2024: Third Quarter Results • Reported net sales increased 11.9% to $5.5 billion • Organic net sales increased 11.5% • Reported operating income margin of 19.7% • Adjusted operating income margin increased 130 bps to 24.7% • Reported EPS increased 20.0% to $2.16 • Adjusted EPS increased 16.7% to $2.87 (1) (1) Third Quarter Net Sales G ...